ClinicalTrials.gg
CompletedNCT00819468Updated May 14, 2021

Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

A Phase 1 interventional study of Teduglutide in Hepatic Impairment, sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-14.

Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jul 2007, registered Jan 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This is a study to compare the pharmacokinetic profile of teduglutide in healthy participants with normal hepatic function with participants who have moderate hepatic impairment.

Read the detailed description

24 participants (equally divided between participants with normal hepatic function and those with moderate hepatic impairment (defined by the protocol as a Child-Pugh classification of grade B score of 7-9)will be given a single injection of teduglutide (20mg) through subcutaneous injection into the abdomen. Blood samples would be taken within 30 minutes of dose through 24 hours post-dose. Participants in both groups are matched up by sex, age, BMI, and renal function.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.

Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.

First submitted before Shire became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male or female between 18 and 85 years of age
  • of 18 to 40, inclusive
  • (greater) > 50 milliliter per minute(mL/min)
  • Able to understand and willing to sign an form (ICF)
  • Willing and able to be confined at the study site for approximately 2.5 days
  • Female participants who are , surgically sterilized, or women of (WOCBP) using an effective form of during the study
  • WOCBP must have a negative urine beta human chorionic gonadotropin (β-hCG) result at screening (Days -28 to -2) and check-in (Day -1)
  • Negative urine test for selected drugs of abuse and alcohol at screening and check-in (Day-1)

Inclusion for participants with Impaired Hepatic Function (in addition to above criteria):

  • Documented moderately impaired hepatic function defined by a total score of 7 to 9 on the Classification at screening and check-in
  • No change in disease status within the 3 months prior to study entry
  • Abnormal laboratory results that are related to the participants underlying condition clinically stable as deemed by the investigator
  • Abstained from alcohol use within 90 days prior to study entry when hepatic impairment is known to be secondary to alcohol abuse
  • On medication and/or treatment regimen if, in the opinion of the investigator, the underlying disease is under control
  • Participants with normal hepatic function will be matched collectively as a group by gender, age, and BMI with the participants with moderately impaired hepatic function. Participants with normal hepatic function will also be matched on an individually with the participants with moderately impaired hepatic function with regard to renal function In addition to inclusion criteria # 1 to 8, participants with normal hepatic function must also meet the following inclusion criteria to be eligible for participation in this study:
  • Similar level of renal function based on Cockroft-Gault equation as the matched participant with moderately impaired hepatic function
  • Medically healthy with normal or clinically insignificant clinical results at screening and check-in

Exclusion criteria

Exclusion Criteria:

  • Donated 1 pint or more of blood or blood products within 7 days prior to the study, and/or had a blood or plasma donation within 7 days prior to the study
  • Participated in any other drug trial within 30 days prior to study entry
  • Have a level \< 10.0 g/dL at screening (Days -28 to -2)
  • Have any condition that, in the opinion of the investigator or sponsor, would make them unsuitable for the study
  • Participants with Impaired Hepatic Function (in addition to exclusion criteria 1-4):
  • Acceptable score (Grade B, score of 7 to 9), which is associated with conditions such as cancer rather than impaired hepatic function
  • Participants with Normal Hepatic Function (in addition to exclusion criteria 1-4
  • History or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
  • History or evidence of congenital nonhemolytic hyperbilirubinemia
  • History or evidence of gallstone disease or stomach or intestinal surgery, with the exception of appendectomy
  • History or evidence of colorectal cancer
  • History or evidence of malabsorption, pancreatic disease or gastrointestinal disorders, such as irritable bowel syndrome, Crohn's disease or ulcerative colitis
  • Taking prescription or over-the-counter medication (with the exception of daily low dose aspirin regimen and/or )during the 7 days preceding confinement to the clinical research unit, and/or who anticipate a need to use prescription or over-the-counter medication during the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Participants with Moderate Hepatic Impairment

    Participants with moderate hepatic impairment (Child-Pugh score of 7-9) will receive 20 mg of teduglutide.

    Drug: Teduglutide

  • Active comparator
    Healthy Volunteers

    Healthy volunteers with normal hepatic function matched to hepatic impaired participants by age, gender, BMI, and renal function as measured by creatinine will receive 20 mg of teduglutide.

    Drug: Teduglutide

Interventions

  • Participants will receive 20 mg dose of lypholized powder of teduglutide mixed with sterile water and injected subcutaneously into the abdomen.

    Also known as: GATTEX

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Time Zero to Time of the Last Measurable Concentration (AUC0-last)

    AUC0-last of Teduglutide will be evaluated.

    Time frame: Pre-dose, 3 hours and 24 hours post-dose

  2. Maximum concentration (Cmax)

    Cmax of Teduglutide will be evaluated.

    Time frame: Pre-dose, 3 hours and 24 hours post-dose

  3. Elimination Half-Life (t1/2)

    t1/2 of Teduglutide will be evaluated.

    Time frame: Pre-dose, 3 hours and 24 hours post-dose

Secondary outcomes

  1. Number of participants with Adverse events (AEs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical/medicinal product which includes an exacerbation of a pre-existing illness, sign, symptom, or clinically significant laboratory test abnormality that is detected or diagnosed after study drug administration, pretreatment or post-treatment events that occur as a result of protocol-mandated procedures. An AE does not necessarily have to have a causal relationship with study drug.

    Time frame: From start of study treatment to follow up (up to 9 days)

07

Study locations

1 site
  • University of Miami Clinical Pharmacology Unit
    Miami, Florida 33136, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2007 to primary completion in Aug 2007, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2009
First posted
Jan 9, 2009
StartActual
Jul 26, 2007
Primary completionActual
Aug 23, 2007
CompletionActual
Aug 23, 2007
Last update
May 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00819468
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jan 9, 2009
Start date
Jul 26, 2007
Primary completion
Aug 23, 2007
Completion
Aug 23, 2007
Last update
May 14, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion